SCYX News and Press, SCYNEXIS Inc. From 03/02/21

Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including those caused by resistant strains 1 st Interim a...

JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Offi...

Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while preserving SCYNEXIS’ global rights to the drug Ampli...

Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations. Shanghai Microport Cardioflow Medtech, a spinout from China medical device maker Microport, completed a $324 million IPO in Hong Kong. Hangzhou Zhongmei Huadong ...

SCYNEXIS ([[SCYX]] +0.2%) and Hansoh Pharmaceutical Group announces a strategic partnership and license agreement for the development and commercialization of Ibrexafungerp for the Greater China region.Ibrexafungerp is an oral antifungal product candidate under regulatory revie...

UTILITY Therapeutics Joins Antimicrobials Working Group PR Newswire WASHINGTON , Feb. 17, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the missio...

Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China SCYNEXIS will receive a $10 million upfront payment and will also be eligible to receive development and commerci...

Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia , provides fully integrated R&D, manufacturing, and commercial capabilities to accelerate entry of ibrexafungerp in the global market SCYNEXIS to receive milestone ...

WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment o...

Adamis Pharmaceuticals (ADMP) +66% as its epinephrine products added to Walgreens club.Climate Change Crisis Real Impact I Acquisition Corporation (CLII) +48% as EV fast charging company EVgo to go public via SPAC.SCYNEXIS (SCYX) +36%.Humanigen (HGEN) +20% on expanding partners...